曲安奈德联合A型肉毒毒素优于单药治疗瘢痕的转化研究
该转化试点研究在患者瘢痕左右半侧随机对照比较曲安奈德(TAC)联合A型肉毒毒素(BTX-A)与BTX-A单药治疗3次(间隔4周)的疗效,并以大鼠烧伤瘢痕模型探讨机制。联合治疗在瘢痕厚度(V2-V4)和温哥华瘢痕量表评分(V3、V4)上优于单药,疼痛和瘙痒无显著差异;动物实验显示联合治疗更有效降低瘢痕厚度、TGF-β、CTGF及I/III型胶原比值,并提高层粘连蛋白/纤连蛋白比值。
要点
- 联合治疗在瘢痕厚度和温哥华瘢痕量表评分上优于BTX-A单药。
- 疼痛和瘙痒评分两组间无显著差异。
- 机制可能与下调TGF-β和CTGF、抑制成纤维细胞增殖活化有关。
核心结论
- TAC联合BTX-A较BTX-A单药更有效改善瘢痕厚度和温哥华瘢痕量表评分。
- 联合治疗未在疼痛和瘙痒改善上显示优于单药。
- 联合治疗可能通过下调TGF-β和CTGF抑制成纤维细胞增殖活化,促进瘢痕重塑。
研究设计与样本
- 临床部分:每位患者瘢痕随机分为两等份,分别接受TAC+BTX-A和BTX-A单药治疗,共3次,间隔4周。
- 动物部分:大鼠烧伤瘢痕模型分为5组:假手术组、未治疗烧伤组、TAC组、BTX-A组和TAC+BTX-A组。
主要发现
- 两种治疗均降低瘢痕厚度、温哥华瘢痕量表评分、疼痛数字评分和瘙痒视觉模拟评分。
- 联合治疗在V2至V4访视时瘢痕厚度降低优于BTX-A单药。
- 联合治疗在V3和V4访视时温哥华瘢痕量表评分降低优于BTX-A单药。
- 疼痛数字评分和瘙痒视觉模拟评分两组间无显著差异。
- 动物实验显示联合治疗更有效降低瘢痕厚度、TGF-β和CTGF水平及I/III型胶原比值,并提高层粘连蛋白/纤连蛋白比值。
关键数值与推荐
- 临床评估时间点:每次干预前(V1、V2、V3)及末次治疗后4周(V4)。
- 瘢痕厚度用卡尺测量,瘢痕状况用温哥华瘢痕量表评估。
- 疼痛用数字评分量表评估,瘙痒用视觉模拟评分评估。
- 治疗共3次,间隔4周。
临床怎么用
- 对于增生性瘢痕和瘢痕疙瘩,可考虑TAC联合BTX-A注射以更有效改善瘢痕厚度和整体瘢痕状况。
- 联合治疗对疼痛和瘙痒的改善与BTX-A单药相当,选择方案时应综合考虑。
- 联合治疗可能通过抑制TGF-β/CTGF通路促进瘢痕重塑。
局限性
- 本研究为试点研究(pilot study),样本量未报告。
- 临床部分为自身左右半侧对照,未设安慰剂对照。
- 动物实验结论需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of combining triamcinolone acetonide (TAC) and botulinum toxin type A (BTX-A) to treat hypertrophic scars and keloids remains unclear. OBJECTIVES: This pilot study aimed to compare the clinical efficacy of BTX-A monotherapy and TAC + BTX-A combination therapy in improving scar conditions and to investigate potential mechanisms with a rat burn scar model. METHODS: This study was conducted between March 2022 and December 2024. Each patient's scar was randomly divided into 2 equal parts, with 1 part receiving TAC + BTX-A and the other BTX-A alone for 3 sessions at 4-week intervals. Scar thickness was measured with calipers, and the Vancouver Scar Scale (VSS) was administered to assess scar condition. Pain and pruritus were evaluated with a numeric rating scale (NRS) and visual analog scale (VAS), respectively, before each intervention (V1, V2, V3) and 4 weeks after the last session (V4). In the animal study, rats with burn scars were assigned to 5 groups: sham, untreated burn, TAC, BTX-A, and TAC + BTX-A. Scar thickness and expressions of alpha smooth muscle actin (α-SMA), transforming growth factor beta (TGF-β), connective tissue growth factor (CTGF), collagen I/III, laminin, and fibronectin were analyzed histologically. RESULTS: Clinically, both therapies reduced scar thickness, VSS, NRS, and VAS scores. However, combination therapy showed superior reductions in scar thickness (V2-V4) and VSS scores (V3, V4) compared to BTX-A monotherapy. No significant differences were observed in NRS and VAS scores. The animal study confirmed that combination therapy more effectively reduced scar thickness, TGF-β and CTGF levels, and the collagen I/III ratio, and increased the laminin/fibronectin ratio. CONCLUSIONS: TAC + BTX-A combination therapy enhances scar reduction by more effectively suppressing fibroblast proliferation and activation through TGF-β and CTGF downregulation, promoting scar remodeling.
引用
- Huang SH, Wang WC, Chuang HY, et al. Enhanced Scar Reduction With Triamcinolone Acetonide and Botulinum Toxin A Combination Therapy Compared to Botulinum Toxin A Monotherapy: A Translational Pilot Study. Aesthet Surg J. 2025. PMID: 40474473. doi:10.1093/asj/sjaf094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。